Species specific hematopoietic growth factor which stimulates the development of committed progenitor cells to monocytes/macrophages. Also potentiates phagocytic activity and monocyte-mediated tumor cell cytotoxicity. Heavily glycosylated homodimer; produced in response to specific activating agents by a variety of cell types including monocytes, fibroblasts and endothelial cells. In humans, several molecular species have been identified which are produced via alternative splicing mechanisms from a single-copy gene. The primary transcripts include a 90 kDa glycoprotein, which is the principle form detected in serum and urine, and a fully bioactive, membrane-associated 40-50 kDa dimer. Murine M-CSF is similar to the human long form. Isoln from human urine: E. R. Stanley et al., Fed. Proc. 34, 2272 (1975); from cultured human pancreatic carcinoma cells: M. Wu et al., J. Biol. Chem. 254, 6226 (1979). Purification of murine M-CSF: E. R. Stanley, P. M. Heard, ibid. 252, 4305 (1977). Characterization of human M-CSF: S. K. Das et al., Blood 58, 630 (1981); K. Motoyoshi et al., ibid. 60, 1378 (1982). Cloning of short form (human clone pcCSF-17): E. S. Kawasaki et al., Science 230, 291 (1985); of long form (human clone p3ACSF-69): G. G. Wong et al., ibid. 235, 1504 (1987). Review of molecular biology: E. S. Kawasaki, M. B. Ladner, Immunol. Ser. 49, 155-176 (1990); of bioactivity and clinical studies: D. H. Munn, N.-K. V. Cheung, Semin. Oncol. 19, 395-407 (1992).
Nonglycosylated, 218 amino acid polypeptide produced in E. coli by recombinant DNA technology. Prepn and renaturation into bioactive homodimer: R. Halenbeck et al., Biotechnology 7, 710 (1989). Clinical evaluation in invasive fungal infections: J. Nemunaitis et al., Blood 82, 1422 (1993). Immunomodulatory effects and pharmacokinetics: R. M. Bukowski et al., J. Clin. Oncol. 12, 97 (1994).
Immunomodulator.
Immunomodulator